Start up developes T cell silencer for autoimmune diseases
December 2014
Otto-von-Guericke University Magdeburg, Magdeburg, Germany
Mistargeted T-cell activity can lead to episodic inflammatory reactions, which are a characteristic of autoimmune diseases, thus prevention of these cascades is an important therapeutic goal. Common immunosuppressants or cortisone do not act at the origin of the disease and therefore cannot stop its progression. Based on in vitro experiments with human peripheral blood cells from voluntary donors, so-called T-cell silencers could be identified. These may have the potential to prevent diseases such as multiple sclerosis, Crohn's disease or rheumatoid arthritis directly at its origin, at the unwanted T cell activity.
Selective targeting of transforming growth factor-beta1 into TCR/CD28 signalling plasma membrane domains silences T cell activation
Thomas Harder
Added on: 04-30-2021
[1] https://biosignaling.biomedcentral.com/articles/10.1186/s12964-014-0074-6[2] www.tranquil-immune.de/
